Advancing Real-World Evidence in Neuromodulation Through a Global Registry
The International Neuromodulation Registry represents a significant step forward in collecting standardized data on therapies used for chronic pain and neurological conditions. Led by an international team of experts, this initiative addresses longstanding challenges in generating reliable evidence across diverse healthcare settings.
Background on Neuromodulation Therapies and Evidence Gaps
Neuromodulation therapies, including spinal cord stimulation and other device-based approaches, have grown in use for managing conditions like failed back surgery syndrome and neuropathic pain. However, existing studies often rely on small samples or single-center data, limiting their applicability. The registry aims to overcome these issues by pooling information from multiple countries using consistent protocols.
Real-world evidence from such platforms can complement randomized trials by capturing outcomes in everyday clinical practice. This approach supports better decision-making for clinicians, regulators, and payers seeking to understand long-term effectiveness and safety.
Design and Structure of the Multinational Platform
The registry employs a federated data submission model. Participating centers submit a minimum dataset covering patient demographics, clinical characteristics, procedural details, device information, and patient-reported outcomes. This structure allows flexibility for national registries or individual sites while maintaining standardization.
Phase 1 implementation focused on spinal cord stimulation procedures, running from January 2025 through April 2026. Centers could choose direct entry or bulk upload methods, accommodating varying technical infrastructures across regions.
Organizational Governance and Oversight
A multi-tier board and specialized committees manage operations. These groups handle ethics review, data governance policies, and publication standards. The framework ensures transparency and accountability as the project scales internationally.
Early participation involved coordination through the International Neuromodulation Society, drawing on expertise from surgeons, researchers, and administrators in multiple nations.
Ethical Framework and Data Protection Measures
Ethical considerations form a core component, with dedicated oversight for patient consent, data privacy, and responsible use of information. The design aligns with international standards for observational research, emphasizing protection of sensitive health data while enabling valuable scientific insights.
Committees review protocols to balance research needs with individual rights, supporting sustainable multinational collaboration.
Photo by Abdulai Sayni on Unsplash
Early Implementation Results and Participation Metrics
By the reporting period, 45 centers across nine countries had confirmed involvement in Phase 1. Sites progressed through onboarding, training, and initial data submissions at varying paces, highlighting the practical aspects of launching such a platform.
The mix of submission pathways demonstrated feasibility despite differences in local systems. No clinical outcome analyses were conducted at this early stage, as the focus remained on operational setup and data collection infrastructure.
Key Contributors and International Collaboration
The publication credits a broad team including Philippe Rigoard, Catherine M. Castillo, Maarten Moens, Lisa Goudman, Jan Willem Kallewaard, Kliment Gatzinsky, Dirk Rasche, Denys Fontaine, Vivek Mehta, Ashish Gulve, Stefanos Korfias, Gul Koknel Talu, Witold Libionka, Amine Ounajim, Manuel Roulaud, Richard Armstrong, Oge Swaby, Richard Hewitt, Tia Sofatzis, Marc Russo, and Lawrence Poree, among others associated with the INR Consortium.
This collaboration spans institutions in Europe, the UK, and beyond, reflecting the registry's global ambitions. For the full details, refer to the original publication at https://www.sciencedirect.com/science/article/abs/pii/S1094715926006264.
Potential Impacts on Clinical Practice and Research
As data accumulates, the registry is positioned to support benchmarking of outcomes, post-market surveillance of devices, and evidence for reimbursement decisions. Longitudinal follow-up will provide insights into therapy durability and patient selection criteria.
Stakeholders including physicians, device manufacturers, and health authorities stand to benefit from more robust datasets that reflect real-world diversity.
Challenges in Multinational Data Collection
Early limitations include the registry's developmental stage, predominant European participation in Phase 1, and the observational nature of the data. Biases common to such studies will require careful statistical handling in future analyses.
Expanding recruitment and standardizing follow-up protocols will help address these issues over time.
Future Outlook and Expansion Plans
Broader international involvement and accrual of follow-up data promise to enhance the platform's value. Pre-specified analytical methods will guide subsequent research outputs, potentially informing guidelines and policy.
The initiative underscores the role of professional societies in fostering large-scale evidence generation for emerging medical technologies.
Photo by Brett Jordan on Unsplash
Implications for Academic and Research Communities
Researchers and trainees interested in health data science, clinical outcomes research, or neuromodulation may find opportunities to engage with similar platforms. The model offers lessons in governance and federated data sharing applicable across medical fields.
Institutions seeking to participate can explore resources through the International Neuromodulation Society and related networks. Additional context on global research collaborations is available via the registry's site at https://internationalneuromodulationregistry.org/ and ClinicalTrials.gov entry NCT07354243 at https://clinicaltrials.gov/study/NCT07354243.
